Patients in the UK (n =894) and Japan (n =3158) were prospectively enrolled and were similar in terms of sex (∼60% men) and median age (∼77 years). Models predicted that British patients would have a higher mortality than Japanese, which was indeed true both for in-hospital (4.8% vs. 2.5%) and 180-day (20.7% vs. 9.5%) mortality. The model c-statistics for the published/derivation (range 0.70-0.76) and Japanese (range 0.75-0.77) cohorts were similar and higher than for the UK (0.62-0.75) but models consistently overestimated mortality in Japan. For in-hospital mortality, the OPTIMIZE-HF model performed best, providing similar discrimination in published/derivation, UK and Japanese cohorts 
Introduction
The prevalence of heart failure is rising due to an ageing population and longer survival after the onset of cardiovascular diseases, including heart failure.
1 -4 Improvements in care have failed to stem a rising tide of heart failure-related hospital admissions. Annually, heart failure is the primary reason for >200 000 admissions in Japan, 2, 5 >80 000 in the United Kingdom (UK) 6 and about one million in the United States of America (USA). 7 Despite advances in the management of chronic heart failure, mortality amongst patients hospitalized with worsening heart failure remains high, and no intervention has been convincingly shown to improve outcome. 8 -15 Prognostic models for hospitalized heart failure (HHF) derived from surveys, registries and randomized clinical trials have identified many variables that are associated with outcome.
16 -27 Knowing a patient's risk may help guide management, including the intensity of follow-up, the urgency of advanced interventions, or the need for palliative care. Moreover, some prognostic variables, such as renal function or serum potassium concentration, might be therapeutic targets. However, prognostic models have been developed primarily in patients of European origin and in the USA. It is unclear whether these published models predict outcome in other geographic regions with different health care systems or other ethnic groups. Important regional differences exist not only in terms of health economy, medical infrastructure and management but also patient characteristics and their adherence to medical advice and lifestyle. 28 -31 Accordingly, we investigated the validity of five published HHF mortality prediction models for cohorts of patients enrolled in the UK and Japan.
Methods

Data sources
The UK HHF cohort comprised registry data from two National Health Service (NHS) hospitals in London and one in Kingston-upon-Hull, 32 each serving a local population of approximately 500 000 people and participating in the NHS England and Wales National Heart Failure Audit. 6 Between 2011 and 2013, 894 patients were prospectively enrolled. Data were generally acquired within hours of admission. This was part of a national survey initiated by the NHS which provided ethical oversight.
The WEst Tokyo Heart Failure (WET-HF) registry is an ongoing, multicentre, prospective observational registry of HHF in five large academic medical centres in metropolitan Tokyo (East Japan) that enrolled 2407 patients between 2011 and 2015. 33 The National cerebral and cardiovascular centre for acute DEcompensated heart Failure (NaDEF) registry enrolled 751 HHF patients prospectively at a single centre in Osaka (West Japan) between 2013 and 2015 based on the same inclusion/exclusion criteria as those in the WET-HF registry. 34 Data in both registries were also generally acquired within hours of admission. The study protocols of the both Japanese registries were approved by the respective institutional review boards, and were registered at the Japanese UMIN Clinical Trial Registration (UMIN000001171 and UMIN000017024, respectively). 
Mortality prediction models and study population
We carried out a detailed search using the MEDLINE/PubMed and Embase search engines and identified all the HHF mortality prediction models based on a specific search strategy (online supplementary Appendix S1). This search strategy has been previously validated with high sensitivity and specificity for finding prediction research in MEDLINE. 35 Among these 28 models, five HHF models 18, 19, 21, 26, 27 were chosen based on the covariates available in both the UK and Japanese datasets (15 models were excluded due to lack of specific variables which are required to calculate the risk score and 8 models were excluded due to lack of availability of in-hospital mortality and 180-day outcomes) (Figure 1 ) for external validation in the UK and Japanese cohorts ( Table 1, and online supplementary Tables S1A, S2 , S3A and S4A). The HHF models identified were: (i) the Get With The Guidelines-Heart Failure (GWTG-HF) risk score, 18 (ii) the Acute Decompensated Heart Failure National Registry (ADHERE) model, 21 (iii) the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) risk score, 19 (iv) the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) risk score, 27 and (v) the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) risk score. 26 For each prediction model, we replicated the methods used by the original authors to calculate the predicted mortality for patients in the UK and Japanese cohorts. Racial origin was not collected but the vast majority of patients in the UK were of European origin and in Japan were Japanese. Accordingly, we did not use the ethnicity variable in the model, which applies mainly to people of African-American origin.
In the UK, blood urea nitrogen (BUN) was missing in 41% of cases, reducing the population available for analysis of all models other than OPTIME-CHF, which used serum creatinine. Therefore, we repeated all other models, substituting BUN with serum creatinine using the formula shown in the online supplementary Tables S1B, S3B and S4B. In the ADHERE registry, we used the coefficients of BUN, systolic blood pressure (BP), heart rate (HR) and age from their multivariable model to calculate the log odds of in-hospital mortality (0.0212 × BUN -0.0192 × systolic BP + 0.0131 × HR + 0.0288 × age -4.72) as shown in the original paper. The OPTIME-CHF risk score was developed to predict 60-day mortality but because 60-day mortality was not recorded for the UK, the score was applied for 90-day mortality in each dataset.
Forty-one per cent (n =373) of UK patients had missing data on BUN and 27% (n = 845) of Japanese patients did not have a record of New York Heart Association (NYHA) class. We therefore compared baseline characteristics and outcomes in British patients with and without BUN and in Japanese patients with and without a record of NYHA class. Survival status on days 30, 90 and 180 was recorded rather than the precise date of death. Some patients did not have data on survival status on day 30 (n = 68 in the UK, n = 792 in Japan), on day 90 (n = 29 in the UK, n = 844 in Japan), or on day 180 (n = 29 in the UK, n = 906 in Japan) from the date of admission.
Statistical analysis
Continuous variables are presented as mean ± standard deviation when normally distributed and otherwise as median and interquartile range Studies finally identified (n = 23) 28 different mortality prediction models 15 models required variables that were not available in our datasets 8 models did not report inhospital or 180-day mortality 5 mortality prediction models for final analyses Figure 1 Search strategy for the published hospitalized heart failure mortality prediction models. AUC, area under the curve; HHF, hospitalized due to worsening symptoms and signs of heart failure.
(IQR). Comparison of differences between groups were made using the unpaired Student's t-test or Mann-Whitney U test for continuous variables, and using chi-squared test or Fisher's exact test for dichotomous variables, where appropriate. After defining predicted mortality (predicted probability of death) for each model using the risk scores or the log odds of mortality in the logistic regression model, we assessed discriminative performance and calibration for each model. Model discrimination was assessed by calculating the c-statistic with the area under the receiver operating characteristic curve. Calibration was assessed by plotting observed against predicted mortality, coefficient of determination (large values of R 2 indicating a better fit) and the Hosmer-Lemeshow goodness of fit statistic [smaller P-values (e.g. P < 0.01) indicating a poor fit]. A high R 2 with a 'significant' P-value suggests that the prediction model has precision but lacks accuracy, which might be improved by introducing a 'correction factor'. All tests were two-tailed, and a P-value of <0.05 was considered statistically significant. All analyses were performed with Stata MP 14. 
Results
Cohort baseline characteristics
Baseline characteristics for British (n = 894) and Japanese (n = 3158) patients are summarized in Table 2 . The median ages of British [76 (IQR 67-83) years] and Japanese [78 (IQR 69-84) years] patients were similar and approximately 60% of each cohort was men. Compared to Japanese patients, British patients were more likely to have severe heart failure as evidenced by worse NYHA classification, lower systolic BP, lower serum sodium concentrations and higher serum concentrations of BUN and creatinine but British patients had higher body mass index. Median systolic BP in derivation cohorts of ASCEND-HF and OPTIME-CHF were 123 and 120 mmHg, respectively, which were more similar to British compared to Japanese patients. Median serum creatinine concentrations of patients in GWTG-HF, Modified OPTIME-CHF score: BUN was replaced with creatinine. * North America (44.9%), Europe (20.8%), Asia Pacific (24.9%), South America (9.4%). † 41.7% of patients in the UK had missing BUN value and hence was replaced with creatinine. ‡ Race was not available in the UK patients; because the assigned score was very low (0-3) and around 3% of population in England is British black, we assigned score 3 in all UK patients.
ASCEND-HF and OPTIME-CHF were also similar to the British cohort at 1.3, 1.2 and 1.4 mg/dL, respectively, but lower amongst the Japanese cohort (1.1 mg/dL). Patients in the derivation cohorts and the UK were more likely to have a reduced left ventricular ejection fraction than in Japan. The prevalence of ischaemic heart disease was higher in each of the derivation cohorts (46-59%) and amongst British patients (48%) compared to the Japanese (25%). Compared to Japanese patients, British patients had shorter length of hospital stay (11 vs. 15 days, P < 0.001); 11.1% of British and 23.8% of Japanese patients were hospitalized for >30 days. British patients had higher in-hospital (4.8% vs. 2.5%, P < 0.001), 30-day (5.7% vs. 2.6%, P < 0.001), 90-day (13.6% vs. 6.0%, P < 0.001) and 180-day mortality (20.7% vs. 9.5%, P < 0.001) ( Table 3) . Despite a higher proportion of patients with heart failure and reduced ejection fraction in the UK being discharged on guideline-directed medical therapy, post-discharge mortality was significantly lower in Japan ( Table 3, and online supplementary  Table S5 ).
In-patient mortality
Risk scores for in-patient mortality for GWTG-HF, modified GWTG-HF and OPTIMIZE-HF and the log odds for mortality . Table 4 ). In the UK, model discrimination improved when BUN was replaced with creatinine, possibly because this increased the number of patients available for analysis, but for Japanese patients replacing BUN with creatinine tended to reduce discrimination (Table 4) . Overall, the OPTIMIZE-HF model, which uses creatinine rather than BUN, provided the best discrimination with remarkably similar c-statistics for the derivation, 19 British and Japanese cohorts (0.753, 0.752 and 0.767, respectively).
Calibration coefficients for in-hospital mortality (Figure 2A -C) were also superior for the OPTIMIZE-HF model compared to other models in both the UK (R 2 = 0.76) and Japan (R 2 = 0.91). Tests for goodness-of-fit consistently overestimated mortality in all models for Japan, especially for patients at lower risk. The OPTIMIZE-HF showed greater accuracy than other in-patient models for the UK and Japan. In Japan, substitution of BUN with creatinine reduced overestimation of mortality leading to some improvement in fit with little effect on calibration coefficients ( Figure 3A and 3B) . Substitution of BUN with creatinine had little influence on model calibration in the UK cohort ( Figure 3A and 3B) . Values are number (%) or median (interquartile range), unless otherwise indicated. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
Post-baseline mortality at 30, 90 and 180 days
For 30-day mortality (ASCEND-HF), the c-statistic for the Japanese and derivation cohorts were similar 27 but lower in the UK. The model calibration coefficient was markedly higher for Japan (R 2 = 0.82) compared to the UK (R 2 = 0.12) but again overestimated mortality in Japan. Substituting BUN with creatinine improved model precision in the UK but not Japan and improved calibration in the UK ( Figure 3D, Table 4 ).
For 90-day (OPTIME-CHF) mortality, the c-statistic for Japanese patients was again similar to that of the derivation cohort 26 but lower for British patients. Model coefficients were high for both cohorts but again overestimated mortality in Japan; substituting BUN with creatinine had little effect on model performance for either cohort ( Figure 3E, Table 4 ).
For 180-day mortality, the ASCEND-HF model c-statistics were similar for the derivation 27 and UK cohorts but higher for the Japanese. and Japanese (R 2 = 0.95) patients but again overestimated mortality in Japan. Substituting BUN with creatinine did not improve model performance ( Figure 3F, Table 4 ).
Discussion
This analysis suggests that at least some published models for predicting mortality in HHF, developed predominantly for patients of European origin enrolled in the USA, provide similar prediction for patients enrolled in our registries in Japan and the UK. Indeed, the ability of the models to predict mortality was somewhat greater for Japanese compared to British patients. This suggests that the variables contributing to these models maintain their relationship to outcome in diverse health care systems and ethnicities. However, the published models consistently overestimated mortality for HHF patients in Japan. These analyses should be confirmed and refined using other similar or larger datasets internationally. For in-patient mortality, the OPTIMIZE-HF model performed well, in terms of discrimination and calibration, in both the UK and Japan. This is remarkable, given the very different lengths of hospital stay in the UK and Japan compared to the USA.
17,19,21,36 -40 Longer hospital stays expose patients to a prolonged period at risk of events, even if they might subsequently lead to lower post-discharge mortality. Interestingly, OPTIMIZE-HF was the only model that used serum creatinine in preference to BUN as a measure of renal dysfunction and adopted serum sodium as a 'U-shaped' risk variable with 140 mEq/L as the nadir of risk. In the UK, improvement in the performance of in-patient and 30-day models by substituting BUN with creatinine might simply be attributed to the ability to include more patients in the analysis. In Japan, the effect of substituting BUN for creatinine in the GWTG-HF and ADHERE in-patient models was complex; model discrimination declined slightly but model calibration improved somewhat for GTWG-HF and overestimation of mortality was reduced in both models. Model coefficients for the 90-and 180-day outcome models were high for both Japan and the UK but again consistently overestimated mortality in Japan, which was a half to a quarter of that predicted. The high model coefficients and consistently lower than predicted mortality for Japanese patients suggest that adding a variable to adjust for ethnicity might improve model calibration. In these longer-term models, substitution of BUN with creatinine had little effect on c-statistics or calibration and only modestly reduced overestimation of mortality in Japan. The high model coefficients and consistently lower than predicted mortality for Japanese patients suggest that adding a variable to adjust for ethnicity might improve model calibration.
Other models for HHF suggest that urea is a better marker of prognosis than creatinine, 24 which is consistent with the reduction in model discrimination after substituting BUN with creatinine in Japan. However, the prognostic superiority of BUN may be modest and creatinine may serve almost as well. 24 Indeed, serum urea, creatinine and their ratio may all provide additive prognostic information. 24, 42 The reason why models using BUN rather than serum creatinine should demonstrate lower model accuracy (discrimination and calibration) in British patients is uncertain. Serum creatinine reflects muscle creatinine turnover, protein intake and renal function. 43 BUN is also influenced by catabolic/anabolic balance but, in addition, a large proportion of urea is reabsorbed by the nephron, especially if the patient is dehydrated or diuretic resistant. Greater muscle mass, differences in diet, the severity of congestion and use of higher doses of diuretics in the UK might all alter the relationships between BUN, creatinine and prognosis.
Health care systems and hospitalization threshold vary widely across world regions; hence it is likely that risk scores provide different performance in different populations. In the present study, British patients had a worse risk profile compared to the Japanese, including lower average systolic BP, left ventricular ejection fraction and serum sodium concentration and worse renal . . . The observed mortality for HHF in the UK was similar to that predicted by the models. In other words, although the mortality associated with HHF may be higher in the UK than in some other countries, this reflects sicker patients, perhaps due to a higher threshold for admission. On the other hand, Japanese patients not only appeared less sick, perhaps reflecting a lower threshold for admission, but also had a much lower than predicted mortality, especially amongst lower risk patients. However, it is possible that models derived from 'sicker' populations in the USA overestimate mortality in 'less sick' patients independent of the world region. We can only speculate as to the reasons for the observed difference in mortality, which may include differences in management, patients' adherence to medical advice and therapy, differences in culture, diet and lifestyle, heart failure aetiology, and genetics. Of note, mortality was higher in the UK despite a higher proportion of patients with heart failure and reduced ejection fraction being discharged on guideline-directed medical therapy. One or more of the above differences might explain this anomaly. Adding a variable to reflect a greater variety of ethnic groups might improve the performance of existing models. 39, 44 Alternatively, the influence of individual covariates could be reassessed in different ethnic groups and a new score developed but this might not capture the wider impact of ethnicity.
Prognostic models that can be applied internationally would have considerable value not only for research but also for auditing the quality of care, although interpretation should be done with care. Development of effective community services for heart failure, a major thrust in the UK, means that many patients who used to be admitted to hospital for care are now managed at home or in day-care facilities. Accordingly, patients admitted to hospital are often sicker and more likely to die. The National Heart Failure Audit for England & Wales reported an in-patient mortality of 9.4% for 32 991 HHF patients in 2013-2014 (although <3.0% if aged <65 years), which is a much higher mortality than that reported in the USA (3.1% in 2010-2013) 45 or Japan (6.4% in 2007-2011). 28 Until an international model to assess prognosis is developed, it may be impossible to determine whether poor outcome for HHF in a country reflects a high or low quality of care. Rather than starting afresh, it seems better to build on existing models, some of which performed well in this analysis. Starting with a model and only adding variables that improve it substantially or simplify it is likely to lead to faster and more certain evolution than re-inventing a new model for each new patient cohort.
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Limitations
Our study population includes patients only from selected academic medical centres in Japan and the UK which may not be representative for the whole population. In our study populations, mortality was lower than that observed in published national data in both countries. However, the difference in mortality between the two countries in our study is quite similar to the difference in mortality observed in national datasets (∼40% higher mortality in UK compared to Japan). Validating prediction models in national datasets is not currently possible since these do not record required variables including BP and laboratory data in Japan or, until recently, the UK. We used the same inclusion/exclusion HHF criteria for both Japanese registries (WET-HF and NaDEF) to increase the power of the analysis and generalizability of the results, although some differences in characteristics and outcomes were observed between these datasets (online supplementary Table S6 ).
Renal function and NYHA functional class are key determinants of prognosis in patients with heart failure. 46 The prediction models included in this analysis, with the exception of OPTIMIZE-HF, used BUN as a measure of renal dysfunction but this variable was missing in many patients from the UK. Moreover, NYHA functional class was often missing in Japanese patients. Some significant differences in baseline characteristics and outcomes were observed amongst patients who did or did not have these data recorded. Patients who had a missing BUN appeared sicker while patients without a record of NYHA class appeared less sick (online supplementary Table  S7 ). However, supplementary analysis restricted only to patients without missing BUN and NYHA data and using BUN showed similar results to the main analysis (online supplementary Table S8 and supplementary Figure S1 ).
Fortunately, serum creatinine was available in >99% of patients allowing many more patients to be included in the analysis when used instead of BUN. This may explain why the OPTIMIZE-HF model performed well in the UK and why substitution of BUN with creatinine improved the performance of some models for the UK cohort. The failure of similar substitution to improve discrimination in Japanese patients supports the notion that the improvement in the c-statistic in the UK was due to the inclusion of more patients rather than creatinine being a superior prognostic marker.
. We excluded 23 out of 28 published mortality prediction models either because our data lacked specific variables that the models required or because they did not report on in-hospital or 180-day mortality.
The OPTIME-CHF model was developed for 60-day mortality, but as only 90-day mortality was recorded in the UK, we used this time-frame instead. As most deaths occurring in the first 90 days will have occurred within 60 days, this is unlikely to make a major difference.
The OPTIME-CHF and the ASCEND-HF models were developed on patients who consented to participate in a randomized controlled trial. Such patients may not be epidemiologically representative and the effects of excluding patients who were not approached to participate or who declined are uncertain.
Conclusions
Our analysis shows that existing prediction models predominantly derived from the USA population and health care system provide fairly good discrimination for mortality amongst patients with HHF in the UK and Japan but overestimate mortality in Japan. Existing models could provide the basis for a universal mortality prediction model for HHF but might require modification depending on ethnicity. Further external validation of prediction models in diverse health care systems should be considered prior to application in routine clinical practice. Identifying the reason why patients in Japan have a better than predicted prognosis would be of great interest.
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